24 results on '"Lam, Wei-Sen"'
Search Results
2. Management Paradigm of Central Nervous System Metastases in NSCLC: An Australian Perspective
3. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in
4. Feasibility of supervised telehealth exercise for patients with advanced melanoma receiving checkpoint inhibitor therapy
5. Feasibility of supervised telehealth exercise for patients with advanced melanoma receiving checkpoint inhibitor therapy
6. Specialist pharmacist consultations with cancer patients in a pharmacist‐led anticancer clinic
7. 635 KEYNOTE-495/KeyImPaCT: updated analysis of a biomarker-directed, randomized, phase 2 trial of pembrolizumab-based combination therapy for non-small cell lung cancer
8. Specialist pharmacist consultations with cancer patients in a pharmacist‐led anticancer clinic.
9. Clinical and therapeutic implications of BRAF mutation heterogeneity in metastatic melanoma
10. Chemotherapy in Malignant Pleural Mesothelioma
11. 457 KEYNOTE-495/KeyImPaCT: interim analysis of a randomized, biomarker-directed, phase 2 trial of pembrolizumab-based combination therapy for non–small cell lung cancer (NSCLC)
12. Intravitreal dexamethasone implant use as first-line therapy for cancer-associated retinopathy
13. Long-term hematologic toxicity of 177Lu-octreotate-capecitabine-temozolomide therapy of GEPNET
14. Increased interdigitation zone visibility on optical coherence tomography following systemic fibroblast growth factor receptor 1‐3 tyrosine kinase inhibitor anticancer therapy
15. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in
16. A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma
17. Final Results of the Dream Trial: A Phase 2 Trial of Durvalumab with First-Line Chemotherapy in Mesothelioma with a Safety Run-In
18. DREAM – a phase 2 trial of DuRvalumab with first line chEmotherApy in mesothelioma: final result
19. DREAM: A phase II study of durvalumab with first line chemotherapy in mesothelioma-First results
20. DREAM: A phase II study of durvalumab with first line chemotherapy in mesothelioma—First results.
21. Clinical and therapeutic implications ofBRAFmutation heterogeneity in metastatic melanoma
22. P2.06-026 A Phase II Trial of the Oral FGF Receptor Inhibitor AZD4547 as 2nd or 3rd Line Therapy in Malignant Pleural Mesothelioma - Trial in Progress
23. P2.06-025 DREAM - A Phase 2 Trial of DuRvalumab with First Line chEmotherApy in Mesothelioma with a Safety Run In
24. Specialist pharmacist consultations with cancer patients in a pharmacist-led anticancer clinic.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.